| Name | Title | Contact Details |
|---|---|---|
Eric Volker |
Founder, VP Account Advisors - Cyber Security and Digital Transformation | Profile |
Phoenix Flavors & Fragrances is a leading developer and manufacturer of customized flavors and fragrances, with over two decades of experience in the industry. The company is dedicated to delivering high-quality, artisanal products that help clients innovate and stay competitive. Phoenix collaborates closely with its customers to create bespoke solutions, ensuring that each product meets the highest standards of quality and performance. Based in New Jersey, Phoenix employs between 501 and 1000 people and has a strong regulatory team and advanced quality assurance laboratories. This enables the company to maintain compliance with industry regulations and adapt to changing consumer preferences. In 2022, Phoenix expanded its capabilities by acquiring Innovative Fragrances, enhancing its offerings in the home fragrance, personal care, candles, and air fresheners markets. The company serves a diverse range of brands across various sectors, including food, beverages, and personal care.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Hadron is a premier A- VIII rated international hybrid fronting carrier, dedicated to transforming the insurance landscape for SMEs and lower middle-market insureds. As a modern market entrant, Hadron boasts a robust backing of $250 million in capital, and a strategic partnership network within the Altamont family. Hadron is an unencumbered, clean insurance entity specializing in custom insurance solutions for todays risk landscape. Our commitment to excellence is demonstrated in our top-tier operational frameworks and cutting-edge technology built to exceed expectations of partners and clients.
NFW is a circularity platform for plastic-free performance materials. NFW follows three Ground Rules in everything we develop: start well, stay clean, end well. While nearly everything in the built world relies on some type of plastic that began as crude oil and that will become plastic pollution, we are establishing a new material reality. We believe all materials should begin and end as nutrients, ready for the next growth cycle—true circularity. Our multi-material platform serves a wide range of industries—from fashion and footwear to automotive and upholstery. NFW technology embeds seamlessly into existing supply chains, enabling the worlds most iconic brands to design and scale products with high-performance, plastic-free materials. NFW makes global brands more sustainable, empowering them to create without plastics. Alongside the boldest brands and visionary designers, we are pioneering a naturally circular, post-oil economy.